FindTrial
Sign In

TK-642 Phase 2 Study

TK-642 Phase 2 Study

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221268
Enrollment
Unknown
Registered
2010-10-18
Start date
2010-10-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uncontrollable cancer pain

Interventions

investigational material(s) Generic name etc : TK-642 INN of investigational material : Methadone Hydrochloride Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Invest

Sponsors

TEIKOKU SEIYAKU CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Japanese cancer patients who can be hospitalized for clinical trial 2)Patients who are 20-74 years old at the time of informed consent 3)Patients who have been received cancer pain therapy with opioid for over 1 week etc.

Exclusion criteria

Exclusion criteria: 1)Patients who have any complications or history of cardiac conduction disturbance 2)Patients who have any complications or history of abnormality of respiratory function 3)Patients with any organic encephalopathies etc.

Design outcomes

Primary

MeasureTime frame
Efficacy and Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026